10-Q: Shattuck Labs Reports Q3 2024 Results, Prioritizes DR3 Program

Shattuck Labs discontinues its SL-172154 program and focuses on its DR3 antagonist program, reporting a net loss of $56.7 million for the first nine months of 2024.

Summary

• Shattuck Labs, a biotechnology company, reported a net loss of $56.7 million for the nine months ended September 30, 2024, compared to a net loss of $69.6 million for the same period in 2023.
• The company's collaboration revenue increased to $5.7 million for the first nine months of 2024, up from $0.9 million in the same period of 2023, primarily due to the Ono Pharmaceutical collaboration.
• Research and development expenses decreased to $51.8 million for the first nine months of 2024, down from $59.1 million in the same period of 2023, due to reduced spending on the SL-172154 program and other pipeline research.
• Shattuck Labs has discontinued the clinical development of its SL-172154 program and is prioritizing its DR3 program, including SL-325.
• The company's cash, cash equivalents, and investments totaled $90.1 million as of September 30, 2024, which management believes is sufficient to fund operations into 2027.
• Shattuck anticipates incurring restructuring charges between $1.5 million and $1.75 million in the fourth quarter of 2024 related to the discontinuation of the SL-172154 program.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positives such as increased collaboration revenue and a clear strategic focus, the significant net loss, program discontinuation, and restructuring charges temper the overall sentiment. The company's cash runway is a positive, but the risks associated with drug development remain.

Positives

• Collaboration revenue increased significantly, indicating successful partnerships.
• Research and development expenses decreased, reflecting cost management efforts.
• The company has a clear focus on its DR3 program, which has potential.
• Shattuck Labs has sufficient cash to fund operations into 2027.
• The company is advancing its TRIM7 inhibitors through preclinical development.

Negatives

• The company reported a significant net loss of $56.7 million for the first nine months of 2024.
• The discontinuation of the SL-172154 program resulted in restructuring charges.
• The company has an accumulated deficit of $363.0 million as of September 30, 2024.
• The company is dependent on a limited number of contract manufacturers and research organizations.

Risks

• The company is dependent on the success of its DR3 program, particularly SL-325.
• Clinical trials may not be successful, and regulatory approvals may be delayed or not obtained.
• The company may face competition from other companies developing similar therapies.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• The company is subject to risks related to manufacturing, supply chain, and intellectual property.
• The global macroeconomic environment could negatively affect the company's operations.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the near term as it advances its DR3 program and other product candidates. Management believes that the company's cash, cash equivalents and investments are sufficient to fund projected operations into 2027.

Management Comments

• Management believes that the company's cash, cash equivalents and investments of $90.1 million as of September 30, 2024 are sufficient to fund projected operations of the Company for at least the next twelve months.
• Management anticipates incurring restructuring charges between $1.5 million and $1.75 million in the fourth quarter of 2024 related to the discontinuation of the SL-172154 program.

Industry Context

The company's focus on DR3 antagonists aligns with the growing interest in novel immunotherapies for inflammatory and immune-mediated diseases. The discontinuation of the SL-172154 program reflects the challenges and risks inherent in drug development, where clinical trial results can lead to strategic shifts in pipeline priorities.

Comparison to Industry Standards

• Shattuck's decision to discontinue SL-172154 is not uncommon in the biotech industry, where clinical trial failures often lead to program terminations. For example, companies like Agenus and Celldex have also had to discontinue programs due to lack of efficacy or safety concerns.
• The focus on DR3 is a novel approach, and while there are no direct comparables in terms of a DR3 antagonist antibody, companies like Bristol Myers Squibb and Janssen are developing therapies targeting the TL1A/DR3 pathway, which is a related area of interest.
• Shattuck's cash runway into 2027 is relatively strong compared to many other early-stage biotech companies, which often have cash runways of 12-24 months. For example, companies like Xencor and IGM Biosciences have similar cash positions but are also actively raising capital.
• The company's collaboration revenue of $5.7 million is modest compared to larger biotech companies with commercialized products, but it is a positive sign for a company in the clinical development stage. Companies like BioNTech and Moderna have significantly higher collaboration revenues due to their commercialized products and established partnerships.

Stakeholder Impact

• Shareholders may be concerned about the net loss and program discontinuation, but the focus on the DR3 program and the cash runway may provide some reassurance.
• Employees have been impacted by the workforce reduction, which may affect morale.
• Customers and suppliers may be affected by the changes in the company's pipeline and priorities.
• Creditors may be concerned about the company's financial performance, but the cash runway may provide some comfort.

Next Steps

• The company plans to file an Investigational New Drug application for SL-325 in the third quarter of 2025.
• The company will continue preclinical development of its DR3 program and other potential product candidates.
• The company will continue to evaluate options related to the advancement of its platform of mRNA/LNP administered multifunctional GLP-1 constructs.

Key Dates

Keywords

Shattuck Labs, DR3, SL-325, biotechnology, immunotherapy, inflammatory bowel disease, clinical trials, research and development, financial results, restructuring